Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Adage Capital Partners GP L.L.C., the most common co-covered peer. The tracked stories average 2 original sources each. SCYNEXIS, Inc. appears in 1 tracked Biotech story from August 13, 2026.
Last mentioned: Aug 13, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Adage Capital Partners GP L.L.C., the most common co-covered peer. The tracked stories average 2 original sources each. SCYNEXIS, Inc. appears in 1 tracked Biotech story from August 13, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering SCYNEXIS, Inc.. Shared-story counts are live from our verified record — not editorial picks.
SCYNEXIS shorts collapsed 87.6% to 320,181 shares, signaling bear exhaustion, while Ensysce Biosciences short interest exploded 619.9% to 364,278. Focus Universal also saw a 282.8% build, reflecting a stark divergence in microcap biotech sentiment.
Source: tickerreport.com · dailypolitical.com
SCYNEXIS, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
